glp-1 cardiovascular outcomes 2025 news Cardiovascular outcome studies with GLP-1 receptor Cardiovascular Risks after GLP-1 Discontinuation

23 In addition, a provider may prescribe a GLP-1 off label for obesity when that GLP-1 is covered by insurance only if the person has a type 2 diabetes diagnosis

These factors, combined with robust clinical evidence demonstrating efficacy in glycemic control and weight management, ensure North America retains the largest market share for GLP-1 receptor agonists globally

PMC 5114298

In older male patients over 65 years old with diabetes and impaired physical performance, 250 mg NMN supplementation for 24 weeks was safe and tolerated and did not improve grip strength and walking speed [188]

This off-label trend is fueled by TikTok testimonials and celebrity endorsements, often ignoring the clinical guidelines